Theranos announced today that it has entered a confidential settlement agreement with Walgreen Co. and Walgreens Boots Alliance, Inc., resolving all claims among those parties.
August 1, 2017
Theranos finalizes shareholder recapitalization; Transaction unifies major investors around forward-looking business plans.
May 16, 2017
Theranos reaches settlement with Partner Fund Management. Tender offer recapitalizing major shareholders scheduled to close May 15.
May 1, 2017
Company to reimburse more than those whose tests were voided and corrected; Resolution ends all existing and potential claims against Theranos in the state.
April 18, 2017
CMS withdraws revocation of CLIA certificates and reduces civil monetary penalty; Theranos withdraws appeal, completing exit from the clinical lab business.
April 17, 2017
Theranos, Inc. announced that engineering and biomedical device design experts have joined the company’s newly created Technology Advisory Board (TAB).
January 17, 2017
Theranos names operations chief, communications leader, general counsel to executive team; adds molecular pathologist to scientific board.
December 12, 2016
Riley Bechtel Retires from Board; Company to Retire Board of Counselors Structure in Consolidation of Advisory Framework
December 1, 2016
Theranos responds to recent report of a lawsuit filed by an investor.
October 11, 2016
Read CEO Elizabeth Holmes' letter announcing new company focus at Theranos.
October 5, 2016